Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The f... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Voidi... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembro... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nera... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Do... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More
Singapore, May 9 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More